Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

For the Three For the Nine

Months Ended Months Ended

September September September September

28, 30, % 28, 30, %

2008 2007 change 2008 2007 change

Peripheral vascular

segment net sales, as

reported $66,886 $38,713 73% $201,789 $115,835 74%

Less: Atherectomy 20,992 - NA 68,624 - NA

Peripheral vascular net

sales, excluding

atherectomy (non-GAAP) $45,894 $38,713 19% $133,165 $115,835 15%

ev3 Inc.

RECONCILIATION OF NET LOSS TO

NON-GAAP ADJUSTED NET INCOME

(LOSS)

(Dollars in thousands)

(unaudited)

For the Three For the Nine

Months Ended Months Ended

September September September September

28, 30, 28, 30,

2008 2007 2008 2007

Net loss, as reported $(7,310) $(36,512) $(44,502) $(57,877)

Amortization of intangible assets 8,101 3,952 24,285 11,916

Stock-based compensation 3,059 2,470 11,682 7,329

Intangible asset impairment - - 10,459 -

Non-GAAP adjusted net income (loss) $3,850 $(30,090) $1,924 $(38,632)

ev3 Inc.

RECONCILIATION OF NET LOSS PER COMMON SHARE TO

NON-GAAP ADJUSTED


'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/31/2014)... 2014 2014 Market Research ... professional and in-depth research report on the ... information, including Polyacrylamide definition, classification, application, and ... overview. This research covers the international market ... global industry analysis covering macroeconomic environment & ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... SyntheMed, Inc. ("the Company") (OTCBB: SYMD; Pink Sheets: ... on the treatment of diseases characterized by organ-specific cell damage, ... 2011.  The Company changed its name to "Pathfinder Cell Therapy, ... OTC Bulletin Board, changing to a new trading symbol shortly. ...
... 2011 Omeros Corporation (NASDAQ: OMER ... developing and commercializing products targeting inflammation, coagulopathies and ... that Gregory A. Demopulos, M.D., chairman and chief ... Rodman and Renshaw 13th Annual Healthcare Conference taking ...
... The inaugural  European Neurotech Investing ... It features keynotes on the state of the European neurotech ... presentations on next generation treatments emerging in the EU for ... Alzheimer , s, addiction, depression, schizophrenia, Parkinson ...
Cached Biology Technology:Pathfinder, LLC and SyntheMed, Inc. Complete Merger 2Pathfinder, LLC and SyntheMed, Inc. Complete Merger 3High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 2High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 3
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... rise of the Tibetan plateau -- the largest topographic ... for both its profound effect on climate and its ... GSA Bulletin , Katharine Huntington and colleagues employ ... using modern and fossil snail shells to investigate the ... , Views range widely on the timing of ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7
... Massey Cancer Center studying the interaction between the ... gamma as one of the signaling proteins involved ... researchers develop tailored vaccines and other immunotherapeutic strategies ... the manipulation of the immune system ?by introducing ...
... M.D. and Ami Klin are part of a global research ... region of a chromosome that may lead to autism in ... Genetics and also will be published in the journal’s March ... scan. Over 120 scientists from over 50 institutions who formed ...
... cause of high blood pressure lies within the brain, and ... by scientists at the University of Bristol, UK, and is ... Waki, working in a research group led by Professor Julian ... (junctional adhesion molecule-1), which is located in the walls of ...
Cached Biology News:Mechanisms involved with tumor relapse identified 2Autism gene identified by researchers at Yale working with a global research consortium 2Blame the brain for high blood pressure 2
... IMPACT (Intein Mediated Purification with an ... activity of engineered protein splicing elements (termed ... single affinity column (1-4) (Figures 1 and ... protein fusion systems by its ability to ...
... all the reagents required for a fast ... activity in cell and tissue extracts and ... has been tested on samples prepared from ... spleen, and heart muscle from several species, ...
... CHEMICON's Skeletal Myogenesis Kit provides ... C2C12 myoblasts into mature skeletal myotubes. ... kit is a valuable tool in ... and in developing strategies for muscle ...
... Detection Assay is an anchorage-independent growth assay ... most stringent assay for detecting malignant transformation ... (pre-treated with carcinogens or carcinogen inhibitors) are ... medium for 21-28 days. Following this ...
Biology Products: